Daina Graybosch
Stock Analyst at Leerink Partners
(0.86)
# 3,816
Out of 4,944 analysts
110
Total ratings
37.5%
Success rate
-11.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.70 | +185.71% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.91 | +266.49% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $25.69 | -53.28% | 1 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Market Perform | $47 → $9 | $10.11 | -10.94% | 8 | May 14, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $80.30 | +48.19% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.53 | +30.72% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.50 | +263.64% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $72.50 | -46.21% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $23.60 | +90.68% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.52 | +2,602.70% | 4 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $10 | $0.94 | +968.03% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.07 | +334.78% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $9.67 | +292.97% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.58 | +123.46% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $111.00 | +101.80% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.96 | +1,430.61% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.19 | +1,328.57% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.47 | +512.24% | 4 | Feb 25, 2022 |
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.70
Upside: +185.71%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.91
Upside: +266.49%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $25.69
Upside: -53.28%
iTeos Therapeutics
May 14, 2025
Downgrades: Market Perform
Price Target: $47 → $9
Current: $10.11
Upside: -10.94%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $80.30
Upside: +48.19%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.53
Upside: +30.72%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.50
Upside: +263.64%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $72.50
Upside: -46.21%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $23.60
Upside: +90.68%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.52
Upside: +2,602.70%
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $0.94
Upside: +968.03%
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.07
Upside: +334.78%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $9.67
Upside: +292.97%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.58
Upside: +123.46%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $111.00
Upside: +101.80%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.96
Upside: +1,430.61%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.19
Upside: +1,328.57%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.47
Upside: +512.24%